Update shared on15 Aug 2025
Quipt Home Medical’s Future P/E has risen significantly from 15.16x to 20.94x, indicating higher growth expectations relative to earnings, while the analyst price target remains unchanged at CA$6.60.
What's in the News
- Quipt Home Medical received a non-binding buyout proposal from Forager Capital Management at $3.10 per share, a 121% premium above its prior stock price.
- Forager, owner of 9.7% of Quipt, disclosed the offer, which is significantly above typical take-private deal premiums.
- The company was dropped from multiple major Russell indexes, including the Russell 2000, 2500, 3000, and related growth and value benchmarks.
Valuation Changes
Summary of Valuation Changes for Quipt Home Medical
- The Consensus Analyst Price Target remained effectively unchanged, at CA$6.60.
- The Future P/E for Quipt Home Medical has significantly risen from 15.16x to 20.94x.
- The Discount Rate for Quipt Home Medical remained effectively unchanged, at 6.89%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.